Wegovy capsule value exhibits Novo technique in weight reduction drug market
Novo Nordisk plans to promote its newly authorized weight problems capsule on to sufferers at a cheaper price than a competing medication from Eli Lilly, because the Danish drugmaker tries to grab market share amongst shoppers paying money for blockbuster GLP-1 therapies.
Novo will promote the best doses of its Wegovy capsule, cleared final week, at $299 a month for sufferers paying the corporate immediately, based on the drug’s web site. In the meantime, Lilly has stated it plans to promote its weight reduction capsule orforglipron at as much as $399 a month following approval, which is predicted within the subsequent few months.
The Wegovy capsule’s value can also be decrease than the costs of injectable medication when bought on to sufferers — $349 for injectable Wegovy and $449 for Lilly’s Zepbound.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
